Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
NEUREN PHARMACEUTICALS LIMITED (NEU)ASX AI Signals has generated 4 signal for NEU during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest NEU Signals | |
| 30/06/2026 | BUY |
| 25/05/2026 | BUY |
| 24/05/2026 | BUY |
NEU Share Price | |
| Current Price | $16.740 |
| 52 Week High | $21.980 |
| 52 Week Low: | $11.280 |
| Trading at (% of 52 Week High) | 76.16% |
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company focused on developing therapies for serious neurological conditions. Its lead products target disorders such as Angelman syndrome, Rett syndrome, and other neurodevelopmental diseases. The company works on advancing clinical trials to bring new treatments to patients with unmet medical needs.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for NEUREN PHARMACEUTICALS LIMITED is supported by recent positive developments in its drug pipeline and potential market expansion. However, the pharmaceutical sector's inherent regulatory risks and the company's current valuation volatility moderate the confidence level.
In recent weeks, global markets have experienced mixed performance, with smaller-cap indexes like the S&P MidCap 400 and Russell 2000 showing gains despite broader market challenges. Economic uncertainty, particularly around trade policies and interest rates, continues to influence investor sentimen Neuren Pharmaceuticals (ASX:NEU) Full Year 2024 Results
Key Financial Results
Revenue: AU$216.8m (down 6.5% from FY 2023). Net income: AU$142.0m (down 9.6% from FY 2023). Profit margin: 66% (down from 68% in FY 2023). EPS: AU$1.11 (down from AU$1.24 in FY 2023).ASX:NEU Revenue and Expenses Breakdo The analysts covering Neuren Pharmaceuticals Limited (ASX:NEU) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who held Neuren Pharmaceuticals Limited (ASX:NEU) shares for the last five years, while they ga Neuren Pharmaceuticals' (ASX:NEU) stock is up by a considerable 13% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Neuren Pharmaceuticals' ROE today.
Return on equityLatest NEUREN PHARMACEUTICALS LIMITED(NEU) News
Exploring 3 Undervalued Small Caps With Insider Buying In Global Markets
Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat
Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years
Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial